MASSDEVICE ON CALL — Fujifilm Medical Systems launched clinical trials of its 3D digital mammography technology in the U.S. with installation of machines at centers around the U.S.
Trials are set to begin as early as next month, according to a press release. The company announced the launch at a conference of the Radiological Society of North America over the weekend.
"We believe that, when approved by the FDA, Fujifilm’s 3D digital mammography has the potential to become the standard of care," Fujifilm director of modality solutions marketing David Hotchkiss said in prepared remarks. "When it comes to the early detection of breast cancer, radiologists will benefit from powerful 3D technology to elevate their diagnostic confidence using an average glandular dose that is equivalent to 2D full field digital mammography.
The screening technology allows physicians to wear dedicated glasses designed to present 3D images comprised of combined stereo images of the breast, according to a press release.
The system is already commercially available in Europe.
Health industry puts its vote on Marilyn Tavener as head of Medicare
Health groups, including the American Medical Assn., supported the White House’s nomination of Marilyn Tavener as head of the Centers for Medicare & Medicaid Services after Donald Berwick steps down early next month, Healthwatch reported.
HIV prevention gel for women scrapped
Clinical trials of a vaginal gel designed to prevent HIV transmission in women were scrapped when the gel was found ineffective, according to a press release.
Hill-Rom sends top brass to Chicago
Hill-Rom Holdings Inc. (NYSE:HRC) shifted its executive team to offices in Chicago, the Business Courier reported. Company headquarters remain in Batesville, Indiana.
ObamaCare is making the U.S. sick, says senior member of American Civil Rights Union
president Barack Obama’s health care laws have already led to reduced health coverage, increased costs and hiked premiums among other ills, according to an editorial by American Civil Rights Union and Washington Times columnist Robert Knight.
